Tags » GlaxoSmithKline
GlaxoSmithKline (GSK), Merck, Sanofi-Aventis and others are now able to build on their established positions to market their products to Africa’s growing middle classes.
It is obviously in the financial interests of such companies to promote the attractiveness of branded drugs and indeed there is a certain pharmaceutical brand-snobbery among more prosperous Africans in some countries. 520 more words
Response to @GSK: "It is easier to put a man on the moon than develop a #malaria vaccine. For starters, you can see the moon." ―Andrew Witty
The treasurer asked members to consider the stop loss levels for Optimal Payments and Skyepharma. Decided: to increase the stop loss level of Optimal Payments to 20% and leave the level on Skyepharma unchanged, at 15%. 137 more words
Over 70% of paroxetine studies registered at ClinicalTrials.gov (completion date before January 1st, 2011) remain unpublished. This problem is not unique to paroxetine because other blockbuster antidepressants (e.g., fluoxetine and sertraline) have not published over half of their studies.(1) More unpublished paroxetine studies can be identified analyzing data of other registers (e.g., Eudra CT, ISRCTN, Chi-CTR, among others) downloaded from WHO ICTRP.(2) 132 more words
It took less than 2 months for big pharma corporations to get what they wanted. In October I warned about the Reuters report that was meant to support the swift and successful completion of giving producers of experimental ebola vaccines and emergency measures full protection against future claims brought about by their victims. 418 more words
The FTSE 100 fell sharply today, closing down 143 points at 6529, with only 6 of the 100 companies closing up.
Tesco** (TSCO, 174.9p, -6.62%) released it’s near-customary profit warning- and it was big. 295 more words